REMINDER: Our focusIR Investor Webinar takes place TONIGHT with guest speakers from WS Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.
Thanks Neil & Jamie
Brilliant I get it now thanks for the help
Good luck to you both
Thanks Jamie I am new to trading everyday a school day lol
When I look at share trades on LSE I can not find the codes. Do you need to be a premier account holder to see this?
Hi can anyone tell me where to find the Market maker codes on trades
thanks in advance
Paragraph 5 on today's RNS
Technology transfer to Abingdon Health will begin immediately with the aim of manufacturing an equivalent rapid antigen test product which therefore does not require additional clinical validation/regulatory approvals. The agreement with Abingdon Health will provide additional manufacturing capacity that could increase to several millions of tests per month.
Read the whole NEW RNS)
Manufacturing agreement with Abingdon Health for Avacta’s rapid COVID-19 saliva test
WETHERBY & CAMBRIDGE, England--(BUSINESS WIRE)-- Avacta Group plc (AIM: AVCT), the developer of Affimer® biotherapeutics and reagents, is pleased to announce that it has entered into an agreement with Abingdon Health for the manufacture of Avacta’s saliva-based rapid SARS-CoV-2 antigen test as part of its ongoing expansion of manufacturing capacity.
Avacta, in partnership with Cytiva, is developing a rapid test strip for use with patient saliva that aims to provide a result in a few minutes, indicating whether the patient is currently infected with the SARS-CoV-2 coronavirus. The test has the potential to be used for frequent mass testing of the population to promptly identify infectious individuals so that they can be isolated and treated, thereby reducing the spread of infection.
Avacta recently announced a manufacturing partnership with BBI Solutions to develop and validate a scaled-up manufacturing process for the rapid coronavirus antigen test. Avacta, Cytiva and BBI are in the process of technology transfer of the prototype and related manufacturing procedures for the test. Avacta aims to begin clinical validation of the test as soon as possible using the first pilot batches.
Abingdon Health provides innovative rapid testing solutions to a global client base and has Europe’s largest lateral flow test contract manufacturing capacity. Abingdon Health’s two sites in York and Doncaster, UK are able to produce millions of rapid tests per month.
Technology transfer to Abingdon Health will begin immediately with the aim of manufacturing an equivalent rapid antigen test product which therefore does not require additional clinical validation/regulatory approvals. The agreement with Abingdon Health will provide additional manufacturing capacity that could increase to several millions of tests per month.
Dr. Alastair Smith, Chief Executive of Avacta Group commented: “I am delighted to have partnered with Abingdon Health to expand the manufacturing capacity for Avacta’s rapid saliva-based COVID-19 test.
Authorities around the world are now looking to carry-out frequent mass testing to identify the most infectious people promptly in order to reduce infection rates and combat the coronavirus pandemic. That requires a highly specific test to minimize false positives which would otherwise overwhelm healthcare systems. The Affimer reagents that we have generated are very specific to SARS-CoV-2 antigen and we are confident of meeting and exceeding the clinical performance requirements for identifying the most infectious people.
Manufacturing capacity is therefore the key challenge that has to be met in achieving widespread roll-out of Avacta’s saliva-based rapid antigen test. We therefore continue to actively seek additional manufacturing partners globally to be able to provide the volume of tests that will be required in the UK
****************************/rns/announcement/87e2d48c-c872-4431-9831-7cc5613409fd/
Does not require additional clinical validation/regulatory approvals.
Here we go enjoy the ride.... :-)
wow how good would that be, I love the business model
Brilliant thanks for sharing
I,ve got a good holding, however I don't feel confident to top up without some clarity on the up and coming news.
So exciting :-)
We need results. Its got to be soon
Any results will do, I do hope it's this week!!
Fingers crossed everyone
Watched from 190 bought at 319 fingers crossed this has got legs. :-)
Golden eggs, got in early & enjoying the ride